News | July 30, 2009

New Data on Contrast Media, Kidney Damage May Impact Guidelines

July 30, 2009 - The iso-omolar contrast medium iodixanol does not yield lower rates of contrast-induced acute kidney injury (CI-AKI) than low-osmolar contrast media (LOCM), according to a meta-analysis published in the July 2009 issue of JACC: Cardiovascular Interventions.

Could these findings change current ACC/AHA guidelines, which give a class IA recommendation for iso-osmolar contrast media in patients with chronic kidney disease undergoing coronary angiography?

In the study, a team of researchers at the University of Michigan Medical School led by Hitinder Gurm, M.D., analyzed pooled data from 16 trials conducted between 1980 and 2008 that included 2,763 subjects. The studies consistently ascertained renal function data from patients randomized to either LOCM or iodixanol. The primary endpoint for the meta-analysis was the incidence of CI-AKI as defined by each individual study protocol.

Kidney injury occurred in 128 of 1,379 (9.3%) patients who received iodixanol vs. 158 of 1,375 (11.5%) patients who received LOCM. There was a trend toward a reduced relative risk of CI-AKI with iodixanol compared to LOCM as a whole, although the difference was not significant. After looking at individual types of contrast media, iodixanol did offer a significant advantage in some cases (table 1). Because only 1 study used iomeprol, an analysis was not conducted for this agent. Further, the risk of mortality and need for hemodialysis were similar between the iodixanol and LOCM groups.

This is contrary to earlier research suggesting iodixanol caused less kidney damage than LOCM. This conclusion led to the current ACC/AHA guidelines recommending iso-osmolar contrast media in NSTE ACS patients with chronic kidney disease undergoing angiography.

In light of the new data, the ACC/AHA guidelines may change, and subsequently drive the adoption of less expensive imaging alternatives that are just as effective as the more costly iodixanol, such as Bracco’s iopamidol or Isovue.

For more information: www.bracco.com

Related Content

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Overlay Init